* Astria Therapeutics Inc reported a quarterly adjusted loss of 42 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -63 cents. The mean expectation of five analysts for the quarter was for a loss of 42 cents per share. Wall Street expected results to range from -47 cents to -32 cents per share.

* Reported revenue was zero​; analysts expected zero.

* Astria Therapeutics Inc's reported EPS for the quarter was a loss of 42 cents​.

* The company reported a quarterly loss of $24.53 million.

* Astria Therapeutics Inc shares had risen by 1.4% this quarter and gained 45.3% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 2.6% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Astria Therapeutics Inc is $25.00 This summary was machine generated from LSEG data November 14 at 04:02 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.42 -0.42 Met

Jun. 30 2024 -0.38 -0.43 Missed

Mar. 31 2024 -0.36 -0.38 Missed

Dec. 31 2023 -0.78 -0.94 Missed